Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTAGON adjuvant nivolumab after preoperative DCF in resected thoracic esophageal cancer
jRCT1051220153Phase 2Recruiting
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in esophageal cancer. Primary endpoint: Disease-free survival. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1051220153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220153.